Has Pankaj Satija, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,076,065 in general payments to Pankaj Satija, MD across 2,034 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Pankaj Satija, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Pankaj Satija, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Pankaj Satija, MD

Neurology · Houston, TXNPI 1831352616

Payments from drug & device makers

$1,076,065in general payments, 2019–2025

Across 2,034 payments — averaging $529.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$578K
Amgen$180K
Biohaven Pharmaceutical Holding Company Ltd.$82K
Biohaven Pharmaceuticals, Inc.$52K
Lilly USA, LLC$50K
Axsome Therapeutics, Inc.$48K
plus $85K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	714	$577,987
Amgen(2 entities)	275	$180,440
Biohaven Pharmaceutical Holding Company Ltd.	115	$82,024
Biohaven Pharmaceuticals, Inc.	54	$52,453
Lilly USA, LLC	88	$50,449
Axsome Therapeutics, Inc.	34	$47,524
Teva Pharmaceuticals USA, Inc.	61	$39,528
Pfizer	27	$17,855
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	37	$5,611
Medtronic(2 entities)	89	$5,492
Lundbeck LLC	43	$2,345
Abbott	17	$1,757
Daiichi Sankyo Inc.	1	$1,535
UCB, Inc.	41	$1,070
Vertiflex, Inc.	7	$805
Merz North America, Inc.	22	$538
Supernus Pharmaceuticals, Inc.	61	$531
Novartis	38	$523
Nevro Corp.	11	$507
Eisai Inc.	21	$448
Merz Pharmaceuticals, LLC	16	$423
Jazz Pharmaceuticals Inc.	14	$407
Takeda Pharmaceuticals U.S.A., Inc.	15	$379
Genesys Orthopedics Systems, L.L.C.	1	$352
Biogen	15	$334
Inspire Medical Systems, Inc.	3	$328
SK Life Science, Inc.	10	$316
Grifols USA, LLC	17	$293
Boston Scientific	7	$284
Collegium Pharmaceutical, Inc.	16	$238
Upsher-smith Laboratories LLC	13	$237
Biotronik NRO, Inc.	5	$229
Saluda Medical Americas, Inc.	9	$214
Aquestive Therapeutics, Inc.	13	$197
Idorsia Pharmaceuticals US Inc	15	$194
Si-bone, Inc.	2	$191
Tersera Therapeutics LLC	7	$179
GRT US Holding, Inc.	12	$178
Scilex Pharmaceuticals Inc.	10	$164
Arbor Pharmaceuticals, Inc.	12	$158
Livanova USA, Inc.	7	$150
Catalyst Pharmaceuticals, Inc.	6	$124
Azurity Pharmaceuticals, Inc.	6	$99
Argenx US, Inc.	3	$96
Sunovion Pharmaceuticals Inc.	3	$71
Fujifilm Sonosite, Inc.	1	$66
Stimwave Technologies Incorporated	1	$60
MDD US Operations, LLC	3	$53
Globus Medical	2	$52
Vertos Medical, Inc.	3	$50
AstraZeneca	3	$47
Amneal Pharmaceuticals LLC	3	$45
Promius Pharma LLC	3	$44
Zyla Life Sciences, Inc.	2	$41
Avanir Pharmaceuticals, Inc.	2	$38
Vertical Pharmaceuticals, LLC	2	$38
SPR Therapeutics, Inc	1	$34
Averitas Pharma Inc.	1	$28
Johnson & Johnson	2	$28
Redhill Biopharma Inc.	2	$26

How this compares

$1,076,065 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas →

Medicare billing

Part B allowed, 2024

$296,297

Medicare patients

190

Services billed

19,229

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Houston

Jamshid LotfiHouston$6M
Nazanin MajdHouston$5.9M
Aziz ShaibaniHouston$5.5M
John LindseyHouston$3.9M
Joseph KassHouston$3.7M
William OndoHouston$3.1M
Vinay PuduvalliHouston$2.5M
Erin Furr-StimmingHouston$2.1M
Arjun TarakadHouston$2M
Mazen DimachkieHouston$1.6M

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →